US EditionPublished • loading... • Updated
Pfizer’s Art Of The Deal
Pfizer will offer up to 85% discounts on many drugs and launch direct-to-patient sales under a US policy matching prices to the lowest in developed countries.
- On Tuesday, Pfizer and President Trump announced a deal to offer all Pfizer drugs to Medicaid at most-favored nation prices in the U.S.
- The deal followed Trump’s revived policy using tariffs as leverage to push pharmaceutical companies toward price reductions and regulatory clarity.
- Pfizer agreed to list many medicines on the forthcoming TrumpRx website to sell drugs directly to patients at discounts, while ensuring new drugs launch in the U.S. at prices comparable to wealthy nations.
- The White House highlighted discounts of 80% on Eucrisa, 50% on Zavzpret, and 40% on Xeljanz, and analysts called the deal a savvy move securing Pfizer regulatory certainty and tariff relief.
- This agreement signals a potential model for other drugmakers and could reshape pricing transparency and direct-to-consumer sales while offering Pfizer a grace period from tariffs.
Insights by Ground AI
Podcasts & Opinions
11 Articles
11 Articles
Trump announces deal with Pfizer to sell drugs to Medicaid at European prices - West Hawaii Today
President Donald Trump announced Tuesday that his administration had taken a concrete step toward his long-held goal of equalizing prescription drug prices between the United States and other wealthy nations.
Pfizer Reaches Deal on Most-Favored Nation Drug Pricing; Other Pharmas Expected to Follow
Newly launched Pfizer drugs will be priced at parity to prices in comparable developed nations, according to the most-favored nation pricing agreement. But industry observers note that big pharma companies are also raising some prices overseas as part of a strategy to protect U.S. revenue. The post Pfizer Reaches Deal on Most-Favored Nation Drug Pricing; Other Pharmas Expected to Follow appeared first on MedCity News.
Coverage Details
Total News Sources11
Leaning Left1Leaning Right0Center5Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
L 17%
C 83%
Factuality
To view factuality data please Upgrade to Premium
